Advanced Instruments will add antibody and cell-based therapy workflow tech through the acquisition of Solentim. “The coming together of Advanced Instruments’ and Solentim’s core technologies, will be a powerful combination in support of clonal cell line development,” Byron Selman, CEO of Advanced Instruments, said. “With Solentim, we are acquiring innovative technologies that will enhance our ability to support customers in these workflows. We are also adding to our technical capabilities with the addition of imaging, advanced AI capabilities and automation…